Sydney, Australia, April 10, 2025 – Today, Lungscreen Australia, one of the nation’s leading providers of lung screening services, has announced the adoption of Annalise.ai’s advanced clinical decision-support technology to equip its radiologists with cutting-edge artificial intelligence (AI) for faster, more accurate diagnostics.
The deployment of Annalise Enterprise CXR, will help Lungscreen Australia enhance diagnostic accuracy, streamline radiology workflows, and ensure faster, more precise lung disease detection for patients across the country. Access to advanced technology is critical to Lungscreen Australia’s mission of providing equitable, affordable care and improving patient outcomes.
Annalise Enterprise CXR is an artificial intelligence solution that can accurately detect up to 124 findings on chest X-rays, including findings suggestive of conditions that could necessitate urgent care – such as lung nodules. Designed by and for clinicians, this comprehensive decision-support tool acts as a second set of eyes for radiologists, boosting diagnostic confidence while improving efficiency[i].
Following a rigorous evaluation process, Lungscreen Australia elected to officially collaborate with Annalise.ai, leveraging the Annalise.ai technology. Dr Siavash Es’haghi, CEO & Managing Director at Lungscreen Australia, said, “We focus on screening for potentially critical and timesensitive pathologies like lung cancer and occupational lung diseases, and its essential that we do so with the greatest possible accuracy. AI is transforming lung screening, helping us catch life-threatening diseases earlier. Annalise Enterprise CXR provides a critical safeguard, ensuring no detail is overlooked in our mission to save lives.”
Aengus Tran, Co-founder and CEO of Annalise.ai, added, “We are proud to support Lungscreen Australia in delivering world-class, AI-powered lung screening that enhances diagnostic accuracy and speeds up care for Australians at risk of lung disease. This partnership marks a step forward in making AI-assisted lung screening more accessible and effective nationwide. Together, Annalise.ai and Lungscreen Australia are setting new standards for early disease detection and patient care.”
[i]https://www.thelancet.com/journals/landig/article/PIIS2589-7500(21)00106-0/fulltext
